HIV/AIDS

Roche Receives FDA Approval for First HIV-1/HIV-2 Qualitative Test on the cobas 6800/8800 Systems in the Fight Against HIV/AIDS

Basel, 1 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval for the cobas® HIV-1/HIV-2 Qualitative Test for use on the fully automated cobas® 6800/8800 Systems in the U.S. The test provides healthcare professionals with a single result to confirm HIV …

Read More »

FDA Expands Approval of ViiV’s Dovato, a Complete Two-Drug Regimen for Virologically Suppressed Adults with HIV-1

LONDON–(BUSINESS WIRE)–ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration (FDA) approved Dovato (dolutegravir/lamivudine) as a complete regimen for the treatment of HIV-1 infection to replace the current antiretroviral (ARV) regimen …

Read More »

Dewpoint Therapeutics and Merck Partner to Evaluate Novel Approach for the Treatment of HIV

BOSTON–(BUSINESS WIRE)–Dewpoint Therapeutics, the biomolecular condensates company, announced today that it has forged an exclusive collaboration agreement with Merck, known as MSD outside the United States and Canada, to apply Dewpoint’s proprietary platform for condensate-based drug discovery to the development of a novel mechanism for the treatment of HIV. Biomolecular condensates are …

Read More »

FDA Approves ViiV Healthcare’s Rukobia, a First-in-Class Treatment for HIV in Adults with Few Treatment Options

LONDON–(BUSINESS WIRE)–ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration (FDA) has approved Rukobia (fostemsavir), 600 mg extended-release tablets. Rukobia is a novel attachment inhibitor for the treatment of HIV-1 infection …

Read More »

FDA Approves First-Ever Dispersible Tablet Formulation of Tivicay PD, a Once-Daily Treatment for Children Living with HIV

LONDON–(BUSINESS WIRE)–ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration (FDA) has approved Tivicay PD (dolutegravir) tablets for oral suspension, which are used in combination with other antiretroviral agents for the treatment …

Read More »

Global HIV Prevention Study to Stop Early After ViiV’s LAI Formulation of Cabotegravir Dosed Every Two Months Shows Higher Efficacy than Daily Oral PrEP

LONDON–(BUSINESS WIRE)–ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced the interim analysis of the HIV Prevention Trials Network (HPTN) 083 study evaluating the safety and efficacy of investigational, long-acting, injectable cabotegravir for HIV prevention. In the study, …

Read More »

FDA Approves Bristol Myers Squibb’s Pomalyst for AIDS-Related and HIV-Negative Kaposi Sarcoma

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced that Pomalyst® (pomalidomide) was approved by the U.S. Food and Drug Administration (FDA) for patients with AIDS-related Kaposi sarcoma whose disease has become resistant to highly active antiretroviral therapy (HAART), or in patients with Kaposi sarcoma who are HIV-negative.3 Patients with AIDS-related Kaposi sarcoma should …

Read More »

ViiV Healthcare and UNC Chapel Hill Announce Five Year Renewal of Innovative HIV Cure Partnership

LONDON–(BUSINESS WIRE)–ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, and the University of North Carolina at Chapel Hill, a leading global public research university with significant expertise in HIV basic and clinical research, today announced a five-year, $20 million …

Read More »

NIAID Announces HIV Vaccine Trial HVTN 702 Stopped Early for Non-Efficacy

NEW YORK, Feb. 3, 2020 /PRNewswire/ — Today the US National Institute of Allergy and Infectious Diseases (NIAID) announced that HVTN 702, a large-scale HIV vaccine efficacy trial of a canary pox-based vaccine candidate, has been stopped vaccinations because the vaccine does not prevent HIV. HVTN 702 (also known as …

Read More »

Gilead Sciences Licenses Portfolio of HIV Antibodies From The Rockefeller University

FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the company has licensed The Rockefeller University’s portfolio of broadly neutralizing antibodies (bNAbs) against HIV, including the two clinical-stage agents 3BNC117 and 10-1074. These investigational agents have potential for use in HIV long-acting therapies for treatment and prevention, as …

Read More »